Evidence map›Paper›PMID 38375456›Full record

ArticleFrontiers in bioengineering and biotechnology2024

Selective synthesis of rebaudioside M2 through structure-guided engineering of glycosyltransferase UGT94D1.

Lifeng Yang, Mengliang Yang, Zhiwei Deng, Xiaodong Hou, Xiangting Zheng, Qian Ping, Yijian Rao, Jinsong Shi, Yan Zhang

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Frontiers in bioengineering and biotechnology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Review
  2. Review
  3. The progress on stevia (Frontiers in nutrition · 2026
    Review
  4. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Lifeng YangSchool of Life Sciences and Health Engineering, Jiangnan University, Wuxi, China.
Mengliang YangSchool of Biotechnology, Jiangnan University, Wuxi, China.
Zhiwei DengSchool of Biotechnology, Jiangnan University, Wuxi, China.
Xiaodong HouSchool of Biotechnology, Jiangnan University, Wuxi, China.
Xiangting ZhengSchool of Life Sciences and Health Engineering, Jiangnan University, Wuxi, China.
Qian PingSchool of Life Sciences and Health Engineering, Jiangnan University, Wuxi, China.
Yijian RaoSchool of Biotechnology, Jiangnan University, Wuxi, China.
Jinsong ShiKey Laboratory of Carbohydrate Chemistry and Biotechnology, Ministry of Education, School of Life Sciences and Health Engineering, Jiangnan University, Wuxi, China.
Yan ZhangSchool of Life Sciences and Health Engineering, Jiangnan University, Wuxi, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Rebaudioside M2 (Reb M2), a novel steviol glycoside derivative, has limited industrial applications due to its low synthetic yield and selectivity. Herein, we identify UGT94D1 as a selective glycosyltransferase for rebaudioside D (Reb D), leading to the production of a mono

Indexed as

glycosyltransferaseprotein engineeringrebaudioside M2steviol glycosideUGT94D1

Identifiers

PMID38375456
PMCPMC10875103

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.